Standards for the care of people with cystic fibrosis; establishing and maintaining health.

Collapse authors list.
Southern, Kevin ORCID: 0000-0001-6516-9083, Addy, Charlotte, Bell, Scott, Bevan, Amanda, Borawska, Urzula, Brown, Catherine, Burgel, Pierre-Régis, Button, Brenda, Castellani, Carlo, Chansard, Audrey et al (show 35 more authors) , Chilvers, Mark, Davies, Gwyneth, Davies, Jane, De Boeck, Kris, Declercq, Dimitri, Doumit, Michael, Drevinek, Pavel, Fajac, Isabelle, Gartner, Silvia, Georgiopoulos, Anna, Gursli, Sandra, Gramegna, Andrea, Hansen, Carina Me, Hug, Martin, Lammertyn, Elise, Landau, Edwina Eddie C, Langley, Ross, Mayer-Hamblett, Nicole, Middleton, Anna, Middleton, Peter, Mielus, Monika, Morrison, Lisa, Munck, Anne, Plant, Barry, Ploeger, Maarten, Bertrand, Dominique Pougheon, Pressler, Tacjana, Quon, Bradley S, Radtke, Thomas, Saynor, Zoe L, Shufer, Ilan, Smyth, Alan R, Smith, Chris, West, Natalie E and van Koningsbruggen-Rietschel, Silke (2023) Standards for the care of people with cystic fibrosis; establishing and maintaining health. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 23 (1). S1569-1993(23)01727-7-S1569-1993(23)01727-7.

Access the full-text of this item by clicking on the Open Access link.

Abstract

This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on establishing and maintaining health. The guidance is produced using an evidence-based framework and with wide stakeholder engagement, including people from the CF community. Authors provided a narrative description of their topic and statements, which were more directive. These statements were reviewed by a Delphi exercise, achieving good levels of agreement from a wide group for all statements. This guidance reinforces the importance of a multi-disciplinary CF team, but also describes developing models of care including virtual consultations. The framework for health is reinforced, including the need for a physically active lifestyle and the strict avoidance of all recreational inhalations, including e-cigarettes. Progress with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy is reviewed, including emerging adverse events and advice for dose reduction and interruption. This paper contains guidance that is pertinent to all people with CF regardless of age and eligibility for and access to modulator therapy.

Item Type:	Article
Uncontrolled Keywords:	Humans, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Respiratory System Agents, Mutation, Electronic Nicotine Delivery Systems
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	19 Jan 2024 11:28
Last Modified:	23 Mar 2024 01:41
DOI:	10.1016/j.jcf.2023.12.002
Open Access URL:	https://doi.org/10.1016/j.jcf.2023.12.002
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3177913